Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-02

AUTHORS

G Procopio, J Bellmunt, J Dutcher, S Bracarda, J Knox, A Brueckner, I Molnar, B Escudier, T E Hutson

ABSTRACT

BACKGROUND: Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (<55, 55-<65, 65-<75, or ≥ 75 years). METHODS: Dosing patterns, and incidence, prevalence and cumulative incidence of drug-related adverse events (DRAEs) and fatal DRAEs were assessed. RESULTS: Overall, 4684 patients were evaluable (<55 years, n=1126; 55-<65, n=1579; 65-<75, n=1382; ≥ 75, n=559). Treatment patterns were generally similar across subgroups, although sorafenib treatment duration was ∼30% shorter in the ≥ 75-years subgroup. There were no substantial differences in any-grade DRAEs with sorafenib between subgroups. Drug-related adverse events and dose modifications due to DRAEs tended to occur in months 0-3 and declined thereafter; there was no evidence of cumulative toxicity. Fatal DRAEs were rare (0.7% overall; 95% confidence interval, 0.5-1.0%). CONCLUSION: Sorafenib was well tolerated regardless of age in a heterogeneous population of RCC patients. More... »

PAGES

311

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2012.543

DOI

http://dx.doi.org/10.1038/bjc.2012.543

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048528459

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23322192


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Istituto Nazionale dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Department of Medical Oncology 1, Fondazione IRCCS \u2018Istituto Nazionale Tumori\u2019, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Procopio", 
        "givenName": "G", 
        "id": "sg:person.01311056313.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311056313.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Del Mar", 
          "id": "https://www.grid.ac/institutes/grid.411142.3", 
          "name": [
            "Department of Solid Tumor Oncology (Genitourinary and Gastrointestinal), University Hospital del Mar-IMIM, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bellmunt", 
        "givenName": "J", 
        "id": "sg:person.01174264563.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174264563.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "St Luke\u2019s Roosevelt Hospital Center, Beth Israel Medical Center, Continuum Cancer Centers, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dutcher", 
        "givenName": "J", 
        "id": "sg:person.0760406720.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Medical Oncology, Ospedale San Donato-USL8, Arezzo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bracarda", 
        "givenName": "S", 
        "id": "sg:person.0672107754.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672107754.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Princess Margaret Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.415224.4", 
          "name": [
            "Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Knox", 
        "givenName": "J", 
        "id": "sg:person.01270061622.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270061622.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420044.6", 
          "name": [
            "Bayer HealthCare, Leverkusen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brueckner", 
        "givenName": "A", 
        "id": "sg:person.01234471614.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234471614.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bayer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.419670.d", 
          "name": [
            "Bayer HealthCare Pharmaceuticals Inc, Montville, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molnar", 
        "givenName": "I", 
        "id": "sg:person.01307346004.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307346004.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Department of Cancer Medicine, Institute of Gustave-Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "B", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor Scott & White Health", 
          "id": "https://www.grid.ac/institutes/grid.486749.0", 
          "name": [
            "Texas Oncology at Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hutson", 
        "givenName": "T E", 
        "id": "sg:person.0626761272.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626761272.86"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1159/000320223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000798051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.37.1195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003613275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2010.06.121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005134363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa065044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007947936"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24864", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008293686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24864", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008293686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(07)61904-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010511397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djn319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015009768"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.3342", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015052000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.5511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017988502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jjco/hym095", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018595501"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urology.2008.02.061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019712638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq651", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020627241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025111240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0895-4356(99)00098-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028392244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2012.05.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032112381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1372-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032910148", 
          "https://doi.org/10.1007/s00280-010-1372-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa066838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037798278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/1745509x.4.3.253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038334467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.16.9847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041483211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/era.11.153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050269838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejon.2011.05.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051029246"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.23.9764", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052849919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5489/cuaj.978", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072921771"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-02", 
    "datePublishedReg": "2013-02-01", 
    "description": "BACKGROUND: Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (<55, 55-<65, 65-<75, or \u2265 75 years).\nMETHODS: Dosing patterns, and incidence, prevalence and cumulative incidence of drug-related adverse events (DRAEs) and fatal DRAEs were assessed.\nRESULTS: Overall, 4684 patients were evaluable (<55 years, n=1126; 55-<65, n=1579; 65-<75, n=1382; \u2265 75, n=559). Treatment patterns were generally similar across subgroups, although sorafenib treatment duration was \u223c30% shorter in the \u2265 75-years subgroup. There were no substantial differences in any-grade DRAEs with sorafenib between subgroups. Drug-related adverse events and dose modifications due to DRAEs tended to occur in months 0-3 and declined thereafter; there was no evidence of cumulative toxicity. Fatal DRAEs were rare (0.7% overall; 95% confidence interval, 0.5-1.0%).\nCONCLUSION: Sorafenib was well tolerated regardless of age in a heterogeneous population of RCC patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2012.543", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "108"
      }
    ], 
    "name": "Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis", 
    "pagination": "311", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e72e7ad147d40df34a2db4b0daccb4fafaf083feda9008ed61af03f4fc6a2417"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23322192"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2012.543"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048528459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2012.543", 
      "https://app.dimensions.ai/details/publication/pub.1048528459"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000437.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2012543"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.543'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.543'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.543'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2012.543'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      21 PREDICATES      68 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2012.543 schema:about N1120792c5fd9438b879ecb3dea1b2875
2 N2f7afb8a984e4ea2a8c93f7c50f86ae3
3 N67e9bfef994d4e8994a27e40125ae7fb
4 N6e0ed7efb5494a83be87765c27c91c5b
5 N78368eb0be8845c6a13c8429e20d6980
6 N8d22af79baef43a984f15f9e2dc6b5fc
7 N944e17e1624b4281ab0ab825e8428d27
8 N98d66acb723b4ab19ae93cf6f078f990
9 Nbeb65783680f415c8a081f9bd98de5e9
10 Ne83aac3a1dab416f9bea87fea0ed1586
11 Nf385e4a809a749a7b9edaa43181bc168
12 Nf44709922d6744d497b4fe71d9c9a239
13 Nfb1b98e3675b40ce9ee3976031aa7a25
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author N204e96ba9ad640a89469b47327bde337
17 schema:citation sg:pub.10.1007/s00280-010-1372-3
18 https://doi.org/10.1002/cncr.24864
19 https://doi.org/10.1016/j.ctrv.2012.05.001
20 https://doi.org/10.1016/j.ejca.2010.06.121
21 https://doi.org/10.1016/j.ejon.2011.05.001
22 https://doi.org/10.1016/j.urology.2008.02.061
23 https://doi.org/10.1016/s0140-6736(07)61904-7
24 https://doi.org/10.1016/s0140-6736(08)61039-9
25 https://doi.org/10.1016/s0140-6736(11)61613-9
26 https://doi.org/10.1016/s0895-4356(99)00098-0
27 https://doi.org/10.1056/nejmoa060655
28 https://doi.org/10.1056/nejmoa065044
29 https://doi.org/10.1056/nejmoa066838
30 https://doi.org/10.1093/annonc/mdq651
31 https://doi.org/10.1093/jjco/hym095
32 https://doi.org/10.1093/jnci/djn319
33 https://doi.org/10.1159/000320223
34 https://doi.org/10.1200/jco.2003.08.010
35 https://doi.org/10.1200/jco.2008.16.9847
36 https://doi.org/10.1200/jco.2008.19.3342
37 https://doi.org/10.1200/jco.2008.19.5511
38 https://doi.org/10.1200/jco.2009.23.9764
39 https://doi.org/10.1200/jco.2011.37.1195
40 https://doi.org/10.1586/era.11.153
41 https://doi.org/10.2217/1745509x.4.3.253
42 https://doi.org/10.5489/cuaj.978
43 schema:datePublished 2013-02
44 schema:datePublishedReg 2013-02-01
45 schema:description BACKGROUND: Elderly patients tend to be underrepresented in renal cell carcinoma (RCC) clinical trials. The Sorafenib RCC Integrated Database includes data from six clinical trials and two expanded-access studies evaluating sorafenib monotherapy in >4600 patients with RCC. Using this database, sorafenib tolerability and treatment patterns were analysed according to age group (<55, 55-<65, 65-<75, or ≥ 75 years). METHODS: Dosing patterns, and incidence, prevalence and cumulative incidence of drug-related adverse events (DRAEs) and fatal DRAEs were assessed. RESULTS: Overall, 4684 patients were evaluable (<55 years, n=1126; 55-<65, n=1579; 65-<75, n=1382; ≥ 75, n=559). Treatment patterns were generally similar across subgroups, although sorafenib treatment duration was ∼30% shorter in the ≥ 75-years subgroup. There were no substantial differences in any-grade DRAEs with sorafenib between subgroups. Drug-related adverse events and dose modifications due to DRAEs tended to occur in months 0-3 and declined thereafter; there was no evidence of cumulative toxicity. Fatal DRAEs were rare (0.7% overall; 95% confidence interval, 0.5-1.0%). CONCLUSION: Sorafenib was well tolerated regardless of age in a heterogeneous population of RCC patients.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree true
49 schema:isPartOf N8341e651ff9f473c83507a29d8f07373
50 Nc0af47ae9e394b589dff207aa28bce19
51 sg:journal.1017082
52 schema:name Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
53 schema:pagination 311
54 schema:productId N3062151728f341f2af26facc2b6a3452
55 N331ccb3110fd470a94e8e519831aa6a4
56 Nb976c2c069b144499e6f3fe5295f3bec
57 Nc9a09d750c784b7ba59e3e970c7d6c2d
58 Nf173852384bb4f49aa2e9f3f35df6c11
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048528459
60 https://doi.org/10.1038/bjc.2012.543
61 schema:sdDatePublished 2019-04-10T23:13
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Nf540780d4890447ab574a8b991cf07d1
64 schema:url https://www.nature.com/articles/bjc2012543
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N1035e625092b40b78f0561b595ba8232 rdf:first sg:person.01304252172.82
69 rdf:rest Na22053130b70403da7b59701f860ce8b
70 N1120792c5fd9438b879ecb3dea1b2875 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Humans
72 rdf:type schema:DefinedTerm
73 N204e96ba9ad640a89469b47327bde337 rdf:first sg:person.01311056313.05
74 rdf:rest N9214071f5f94419692b68e1c09a8fb25
75 N226187b66e57451ea1d35dcb225d6ac6 schema:name Department of Medical Oncology, Ospedale San Donato-USL8, Arezzo, Italy
76 rdf:type schema:Organization
77 N2f7afb8a984e4ea2a8c93f7c50f86ae3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Aged
79 rdf:type schema:DefinedTerm
80 N3062151728f341f2af26facc2b6a3452 schema:name pubmed_id
81 schema:value 23322192
82 rdf:type schema:PropertyValue
83 N331ccb3110fd470a94e8e519831aa6a4 schema:name readcube_id
84 schema:value e72e7ad147d40df34a2db4b0daccb4fafaf083feda9008ed61af03f4fc6a2417
85 rdf:type schema:PropertyValue
86 N67e9bfef994d4e8994a27e40125ae7fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Phenylurea Compounds
88 rdf:type schema:DefinedTerm
89 N6e0ed7efb5494a83be87765c27c91c5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Antineoplastic Agents
91 rdf:type schema:DefinedTerm
92 N75217c4ba9904201981d7ae77eba169a rdf:first sg:person.01234471614.61
93 rdf:rest Ne833c216736f48a6b0c51fdef4803768
94 N78368eb0be8845c6a13c8429e20d6980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Treatment Outcome
96 rdf:type schema:DefinedTerm
97 N8341e651ff9f473c83507a29d8f07373 schema:volumeNumber 108
98 rdf:type schema:PublicationVolume
99 N8d22af79baef43a984f15f9e2dc6b5fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Carcinoma, Renal Cell
101 rdf:type schema:DefinedTerm
102 N8e3d318f41124470a2a0ddd060316fdb schema:name St Luke’s Roosevelt Hospital Center, Beth Israel Medical Center, Continuum Cancer Centers, New York, NY, USA
103 rdf:type schema:Organization
104 N9214071f5f94419692b68e1c09a8fb25 rdf:first sg:person.01174264563.01
105 rdf:rest N993ceb3cea8e470ebf81053e6ea9313f
106 N944e17e1624b4281ab0ab825e8428d27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Protein Kinase Inhibitors
108 rdf:type schema:DefinedTerm
109 N95609f2a97ac4e109e966cdf6fd763a3 rdf:first sg:person.01270061622.88
110 rdf:rest N75217c4ba9904201981d7ae77eba169a
111 N98d66acb723b4ab19ae93cf6f078f990 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Male
113 rdf:type schema:DefinedTerm
114 N993ceb3cea8e470ebf81053e6ea9313f rdf:first sg:person.0760406720.36
115 rdf:rest Nb0b4fa63f338495cb7e65b03cf227dd8
116 Na22053130b70403da7b59701f860ce8b rdf:first sg:person.0626761272.86
117 rdf:rest rdf:nil
118 Nb0b4fa63f338495cb7e65b03cf227dd8 rdf:first sg:person.0672107754.22
119 rdf:rest N95609f2a97ac4e109e966cdf6fd763a3
120 Nb976c2c069b144499e6f3fe5295f3bec schema:name nlm_unique_id
121 schema:value 0370635
122 rdf:type schema:PropertyValue
123 Nbeb65783680f415c8a081f9bd98de5e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Female
125 rdf:type schema:DefinedTerm
126 Nc0af47ae9e394b589dff207aa28bce19 schema:issueNumber 2
127 rdf:type schema:PublicationIssue
128 Nc9a09d750c784b7ba59e3e970c7d6c2d schema:name doi
129 schema:value 10.1038/bjc.2012.543
130 rdf:type schema:PropertyValue
131 Ne833c216736f48a6b0c51fdef4803768 rdf:first sg:person.01307346004.57
132 rdf:rest N1035e625092b40b78f0561b595ba8232
133 Ne83aac3a1dab416f9bea87fea0ed1586 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Disease-Free Survival
135 rdf:type schema:DefinedTerm
136 Nf173852384bb4f49aa2e9f3f35df6c11 schema:name dimensions_id
137 schema:value pub.1048528459
138 rdf:type schema:PropertyValue
139 Nf385e4a809a749a7b9edaa43181bc168 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Kidney Neoplasms
141 rdf:type schema:DefinedTerm
142 Nf44709922d6744d497b4fe71d9c9a239 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Middle Aged
144 rdf:type schema:DefinedTerm
145 Nf540780d4890447ab574a8b991cf07d1 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nfb1b98e3675b40ce9ee3976031aa7a25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Niacinamide
149 rdf:type schema:DefinedTerm
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1017082 schema:issn 0007-0920
157 1532-1827
158 schema:name British Journal of Cancer
159 rdf:type schema:Periodical
160 sg:person.01174264563.01 schema:affiliation https://www.grid.ac/institutes/grid.411142.3
161 schema:familyName Bellmunt
162 schema:givenName J
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174264563.01
164 rdf:type schema:Person
165 sg:person.01234471614.61 schema:affiliation https://www.grid.ac/institutes/grid.420044.6
166 schema:familyName Brueckner
167 schema:givenName A
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234471614.61
169 rdf:type schema:Person
170 sg:person.01270061622.88 schema:affiliation https://www.grid.ac/institutes/grid.415224.4
171 schema:familyName Knox
172 schema:givenName J
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270061622.88
174 rdf:type schema:Person
175 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
176 schema:familyName Escudier
177 schema:givenName B
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
179 rdf:type schema:Person
180 sg:person.01307346004.57 schema:affiliation https://www.grid.ac/institutes/grid.419670.d
181 schema:familyName Molnar
182 schema:givenName I
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307346004.57
184 rdf:type schema:Person
185 sg:person.01311056313.05 schema:affiliation https://www.grid.ac/institutes/grid.417893.0
186 schema:familyName Procopio
187 schema:givenName G
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311056313.05
189 rdf:type schema:Person
190 sg:person.0626761272.86 schema:affiliation https://www.grid.ac/institutes/grid.486749.0
191 schema:familyName Hutson
192 schema:givenName T E
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626761272.86
194 rdf:type schema:Person
195 sg:person.0672107754.22 schema:affiliation N226187b66e57451ea1d35dcb225d6ac6
196 schema:familyName Bracarda
197 schema:givenName S
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672107754.22
199 rdf:type schema:Person
200 sg:person.0760406720.36 schema:affiliation N8e3d318f41124470a2a0ddd060316fdb
201 schema:familyName Dutcher
202 schema:givenName J
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760406720.36
204 rdf:type schema:Person
205 sg:pub.10.1007/s00280-010-1372-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032910148
206 https://doi.org/10.1007/s00280-010-1372-3
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1002/cncr.24864 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008293686
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1016/j.ctrv.2012.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032112381
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1016/j.ejca.2010.06.121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005134363
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/j.ejon.2011.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051029246
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/j.urology.2008.02.061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019712638
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s0140-6736(07)61904-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010511397
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s0895-4356(99)00098-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028392244
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1056/nejmoa060655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025111240
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1056/nejmoa065044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007947936
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1056/nejmoa066838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037798278
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1093/annonc/mdq651 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020627241
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1093/jjco/hym095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018595501
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1093/jnci/djn319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015009768
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1159/000320223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000798051
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2003.08.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203774
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2008.16.9847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041483211
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2008.19.3342 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015052000
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2008.19.5511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017988502
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2009.23.9764 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052849919
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2011.37.1195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003613275
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1586/era.11.153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050269838
253 rdf:type schema:CreativeWork
254 https://doi.org/10.2217/1745509x.4.3.253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038334467
255 rdf:type schema:CreativeWork
256 https://doi.org/10.5489/cuaj.978 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072921771
257 rdf:type schema:CreativeWork
258 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
259 schema:name Department of Cancer Medicine, Institute of Gustave-Roussy, Villejuif, France
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.411142.3 schema:alternateName Hospital Del Mar
262 schema:name Department of Solid Tumor Oncology (Genitourinary and Gastrointestinal), University Hospital del Mar-IMIM, Barcelona, Spain
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.415224.4 schema:alternateName Princess Margaret Cancer Centre
265 schema:name Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
266 rdf:type schema:Organization
267 https://www.grid.ac/institutes/grid.417893.0 schema:alternateName Istituto Nazionale dei Tumori
268 schema:name Department of Medical Oncology 1, Fondazione IRCCS ‘Istituto Nazionale Tumori’, Milan, Italy
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.419670.d schema:alternateName Bayer (United States)
271 schema:name Bayer HealthCare Pharmaceuticals Inc, Montville, NJ, USA
272 rdf:type schema:Organization
273 https://www.grid.ac/institutes/grid.420044.6 schema:alternateName Bayer (Germany)
274 schema:name Bayer HealthCare, Leverkusen, Germany
275 rdf:type schema:Organization
276 https://www.grid.ac/institutes/grid.486749.0 schema:alternateName Baylor Scott & White Health
277 schema:name Texas Oncology at Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...